Genentech
Executive Summary
Shareholders vote June 8 to accept Roche's $2.1 bil. offer for 60% of the biotech firm. The transaction will become effective after a 20-day waiting period and approval by the Federal Trade Commission, which asked for more information on the proposed deal on March 23. Genentech said both companies are "currently working to satisfy the FTC's request".